Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 15 |
| Active Pipeline (Recruiting Now) | 8 (7) |
| Completed vs Stopped Early | 4 / 3 (20.0%) |
| Median Closed Actual Enrollment | 190 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Westmead Hospital | Westmead, New South Wales | 4 |
| Austin Health | Heidelberg, Victoria | 3 |
| Royal North Shore Hospital | St Leonards, New South Wales | 3 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT06409364 | FLudrocortisone Administration in Aneurysmal Subarachnoid Haemorrhage | Phase II | RECRUITING |
| NCT06058585 | The Chronic Kidney Disease Adaptive Platform Trial Investigating Various Agents for Therapeutic Effect | Phase III | RECRUITING |
Explore interactive annual charts and M&A subsidiary rollups in the The George Institute Interactive Dossier, benchmark peers in Rare Genetic, Women's Health, and Other, or review the Healthcare Price & Patent Cliff Crosswalk.